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Background: Recent studies have shown that fatty acid-binding protein 4 (FABP4) plasma levels are associated
with impaired endothelial function in type 2 diabetes (T2D). In this work, we analysed the effect of FABP4 on the
insulin-mediated nitric oxide (NO) production by endothelial cells in vitro.
Methods: In human umbilical vascular endothelial cells (HUVECs), we measured the effects of FABP4 on the
insulin-mediated endothelial nitric oxide synthase (eNOS) expression and activation and on NO production. We also
explored the impact of exogenous FABP4 on the insulin-signalling pathway (insulin receptor substrate 1
(IRS1) and Akt).
Results: We found that eNOS expression and activation and NO production are significantly inhibited by
exogenous FABP4 in HUVECs. FABP4 induced an alteration of the insulin-mediated eNOS pathway by inhibiting
IRS1 and Akt activation. These results suggest that FABP4 induces endothelial dysfunction by inhibiting the
activation of the insulin-signalling pathway resulting in decreased eNOS activation and NO production.
Conclusion: These findings provide a mechanistic linkage between FABP4 and impaired endothelial function in
diabetes, which leads to an increased cardiovascular risk.
Keywords: Diabetes, Endothelium, Fatty acid-binding protein 4 (FABP4), Endothelial dysfunction, Insulin,
Insulin-signalling pathway, Endothelial nitric oxide synthase (eNOS), Nitric oxide (NO)Introduction
The adipose fatty acid-binding protein (FABP), also
known as FABP4 and aP2, is one of the best charac-
terised intracellular lipid transport proteins [1]. It
belongs to the superfamily of low-molecular-weight
intracellular lipid-binding proteins and plays a central
regulatory role in energy metabolism and inflammation
[2,3]. FABP4 is highly expressed in mature adipocytes
and accounts for approximately 6 % of their soluble pro-
tein. FABP4 is also found circulating in the plasma. In
the last several years, much effort has been focused on* Correspondence: luis.masana@urv.cat
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reproduction in any medium, provided the oruncovering the role of FABP4. However, neither the
secretory pathways nor the functions of circulating
FABP4 are known. We and other authors have shown
that FABP4 levels are increased in obesity, metabolic
syndrome (MS), type 2 diabetes (T2D), and familial
combined hyperlipidaemia or lipodystrophy syndromes,
and these levels are also closely correlated with adverse
lipid profiles and insulin resistance [4-10]. In these stud-
ies, serum FABP4 predicted the development of MS and
atherosclerosis [11,12].
A recent study showed that although serum levels of
both adipocyte and epidermal FABP had associations
with MS, only FABP4 was significantly associated with
increased cardiovascular risk in Chinese adults [13].
Moreover, increased plasma levels of FABP4 in non-
elderly men were independently associated with the
presence of coronary artery disease [14]. A recent study
showed that FABP4 had a direct impact on decreasingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gested that the release of FABP4 in to the bloodstream
could have a direct effect on some peripheral cells and
tissues [15]. In addition, we recently demonstrated that
high levels of plasma FABP4, as other inflammation med-
iators, were associated with endothelial dysfunction
assessed by peripheral artery tonometry [16,17].
Endothelial dysfunction is the first event in the patho-
genesis of atherosclerosis and refers to an imbalance in the
release of vasodilating molecules, such as nitric oxide
(NO) and vasoconstricting factors. NO-dependent vaso-
dilatation is thought to reflect endothelial function, and its
impairment is predictive of future cardiovascular risk
[18,19]. The insulin-signalling pathway in the vascular
endothelium leads to the activation of endothelial nitric
oxide synthase (eNOS) and an increased production of
NO. This pathway involves the insulin receptor-mediated
phosphorylation of insulin receptor substrate 1 (IRS1),
which activates PI3-kinases that then phosphorylates and
activates Akt at Ser473. Akt directly phosphorylates eNOS
at Ser1177, resulting in increased eNOS activation and NO
production. Under pathological conditions, proinflamma-
tory factors cause an impairment in this particular insulin-
signalling pathway in the endothelium, which promotes
endothelial dysfunction [20]. This impairment might be
related to the defective insulin signalling in the endothelial
cells. Moreover, insulin may also activate the pro-
atherogenic mitogen-activated protein kinase (MAPK)
pathway in endothelial cells that leads to increases in the
expression of adhesion molecules and leukocyte adhesion
to the vascular endothelium. In addition, experimental ani-
mals with a vascular endothelial cell-specific insulin recep-
tor deficiency show a reduction in the expression of
adhesion molecules and eNOS mRNA [21].
Although the role of circulating FABP4 on the vascular
endothelium is unknown, a recent study has revealed that
the elevated expression of intracellular FABP4 in endothe-
lial cells contributes to their dysfunction through a reduc-
tion of eNOS [22]. These data along with our own
observations showing the influence of circulating FABP4
on endothelial function warrants testing the hypothesis
that high levels of circulating FABP4 in altered metabolic
conditions could modify the correct function of endothelial
cells and cause endothelial dysfunction by impairments of
the insulin-signalling pathway and NO production. If this
hypothesis were correct, it would contribute to the
mechanisms by which circulating FABP4 contributes to
vascular endothelial dysfunction in diabetes.
Materials and methods
Cell culture and reagents
Human umbilical vein endothelial cells (HUVECs) were
obtained from Cascade Biologics (Invitrogen Life Tech-
nologies, UK). After thawing, cells were seeded in 75-cm2flasks and cultured in medium 200 according to the suppli-
er’s recommendations. Medium 200 was supplemented
with 2 % low serum growth supplement (LSGS) and 1 %
Gentamicin/Amphotericin solution (Invitrogen Life Tech-
nologies, UK). The cells were placed in a humidified incu-
bator at 37 °C and 5 % CO2 until there were enough cells
available for experiments. The HUVEC cells were used at
passage 3 in the current study.
Insulin was purchased from Sigma-Aldrich, Inc.
(USA). Human recombinant FABP4 and anti-FABP4
antibody was from BioVendor (Czech Republic). The
anti-eNOS, anti-phospho-eNOS (Ser1177), anti-Akt, anti-
phospho-Akt (Ser473), antibodies were from Cell Signal-
ing Technology, Inc. (Beverly MA, USA). The anti-IRS1
and anti-phospho-IRS1 (Tyr989) antibodies were from
Santa Cruz (California, USA), and the anti-IgG-HRP
antibody was from Dako (Denmark).
Design of the studies to determine the FABP4 effects
Effect of FABP4 on eNOS activation
Confluent cells were starved in 1 % low serum medium
(without growth factors). To determine whether FABP4
has any effect on the basal eNOS activation, we studied
eNOS phosphorylation at Ser1177. The HUVECs were
incubated with FABP4 (25–100 ng/ml) for 30 min in the
endothelial starvation medium. The treated cells were
rinsed with ice-cold PBS and lysed in lysis buffer, which
was composed of 50 mM Tris–HCl, 150 mM NaCl,
0.1 % SDS, 1 % Nonidet, 0.5 % deoxycholate and prote-
ase inhibitors, and the cells were stored at −80 °C until
they were processed. The total protein concentration
was measured using a Bradford assay (BioRad, USA).
Immunoblot analysis of eNOS phosphorylation at
Ser1177 and total eNOS was performed.
We also examined the effect of FABP4 on the insulin-
stimulated eNOS phosphorylation at Ser1177. The
HUVECs were preincubated with FABP4 (25–100 ng/
ml) for 30 min and were then stimulated with 600 nM
insulin for 30 min in the endothelial starvation medium.
We used the same protocol described above to obtain
the samples. The total protein concentration was mea-
sured using a Bradford assay. Immunoblot analysis of
eNOS phosphorylation at Ser1177 and total eNOS was
also performed.
Effect of FABP4 on the insulin-signalling pathway
Because insulin activates eNOS through IRS1 and Akt,
we investigated whether FABP4 would have any effect
on the insulin-stimulated IRS1 and Akt activation. We
studied the phosphorylation of IRS1 at Tyr989 and of
Akt at Ser473. The HUVECs were preincubated for
30 min with FABP4 (25–100 ng/ml) before a 30-min in-
sulin treatment (600 nM) in the starvation medium.
Treated cells were collected and lysed in lysis buffer, and
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processed. The total protein concentration was mea-
sured using a Bradford assay. Immunoblot analysis of
IRS1 phosphorylation at Tyr989, total IRS1, Akt phos-
phorylation at Ser473 and total Akt was performed.
Immunoblot analysis of eNOS phosphorylation at Ser1177,
total eNOS, IRS1 phosphorylation at Tyr989, total IRS1, Akt
phosphorylation at Ser473, and total Akt, and FABP4
Electrophoresis and immunoblot analysis were per-
formed using the NuPAGE Protein Analysis System
(Invitrogen Life Technologies, UK). The membrane was
blocked with a 2 % ECL Advance Blocking Reagent
(Amersham Biosciences, Fairfield, CT) and was incu-
bated with anti-eNOS, anti-eNOS phosphorylation at
Ser1177, anti-Akt, anti-Akt phosphorylation at Ser473,
anti-IRS1 phosphorylation at Tyr989, anti-IRS1, or anti-
FABP4 antibodies. Antigen-antibody complexes were
detected by incubating the membrane with an IgG-HRP
antibody. The bands were visualised using ECL reagents
(Amersham Pharmacia, Fairfield, CT) with the VersaDoc
image system and were quantified with the Quantity
One analysis software version 4.6.2 (Bio Rad, USA). The
relative levels of the phosphorylated proteins were quan-
tified after being normalised to the total proteins and
were expressed as arbitrary units (AU).
Effect of FABP4 on eNOS mRNA expression
Upon insulin stimulation, the eNOS mRNA was
increased in the vascular endothelial cells. Therefore, we
examined the mRNA expression of insulin-stimulated
eNOS from the FABP4-treated cell lysates. Confluent
vascular cells were preincubated with FABP4 (50–
100 ng/ml) for 30 min and then stimulated with 600 nM
insulin for 24 hours in a supplemented medium. Total
RNA was isolated from the cells using the ABI PRISM
6100 Nucleic Acid PrepStation (Applied Biosystems,
CA, USA). The absorbance at 260 nm was used to meas-
ure the RNA concentration, and an absorbance ratio of
260/280 nm was used to analyse the RNA quality.
Real-time quantitative PCR of eNOS
Total RNA (0.5 μg) was reverse transcribed to cDNA using
Random Hexamers and SuperScript II (Invitrogen Life
Technologies, UK) by following the manufacturer’s proto-
col. TaqMan primers and probes for eNOS and GAPDH
were obtained from validated and pre-designed Assays-on-
Demand products (Applied Biosystems, CA, USA) and
were used in real-time PCR amplifications. The mRNA ex-
pression for each gene and sample was calculated using
the recommended 2-ΔΔCt method. The control group (un-
treated cells) was defined as the calibrator in this experi-
ment. GAPDH was used as a housekeeping gene to
normalise the results of the gene of interest.Nitric oxide assay
Cells were starved for 24 h with 1 % low serum medium
(without growth factors) and then preincubated for 30-
min with FABP4 (25–100 ng/ml) before a 30-min insulin
treatment (600 nM) in the starvation medium. The
supernatants were collected, and the detection of the
NO2 and NO3 anions was performed with the Nitrate/
Nitrite Colorimetric Assay kit (Cayman Chemical, Ann
Arbor, MI) using the Griess reaction and following man-
ufacturer’s instructions. The absorbance of the solution
was read on a spectrophotometer at 540 nm. To quan-
tify the NO production, a standard nitrate curve was
generated in the same medium in which the experiments
were performed. The results were expressed as fold
increases with respect to the insulin treatment.
Statistical analyses
The results are represented as the means ± SD of at least
3 separate experiments. Differences between the means
were determined using a one-way analysis of variance
(ANOVA), which was followed by a Dunnett’s post-hoc
test for multiple comparisons. Differences were consid-
ered significant at P< 0.05. The GraphPad Prism 5.0
Software, Inc. was used for statistical analyses.
Results
FABP4 inhibits eNOS activation and NO production
in HUVECs
To determine whether FABP4 have any effect on eNOS ac-
tivity, we studied the eNOS activation measuring its phos-
phorylation at Ser1177. We found that exposing HUVECs in
the endothelium growth medium (with serum and growth
factors that maintain the basal activation of eNOS) to
FABP4 (25-100 ng/ml) inhibited eNOS phosphorylation at
Ser1177 in a concentration-dependent manner at as early as
30-min of exposure. The maximal inhibition was achieved
at 100 ng/ml of FABP4 (65 %; P< 0.05) (Figure 1A). On
insulin stimulation, eNOS is phosphorylated by the acti-
vation of PI3k/Akt pathway in vascular endothelial cells.
First, we performed a dose–response curve with 100,
300 and 600 nM insulin, and we observed that 600 nM
insulin was required to increase eNOS Ser1177 phosphor-
ylation by 20 % (P< 0.05) (Figure 1B). Therefore, we
performed all of the experiments with 600 nM insulin.
We also performed an insulin time course (10, 30,
60 min), and we observed that the maximal phosphoryl-
ation of eNOS at Ser1177 occurred 30 min after insulin
treatment (26 % increase; P< 0.05) (Figure 1C). We next
analysed whether FABP4 also impairs insulin–induced
eNOS activation and NO production. As shown in
Figure 1D, the addition of insulin increases the
phosphorylation of eNOS at Ser1177, but a 30-min
pretreatment with FABP4 (25–100 ng/ml) inhibits this
insulin-dependent increase by up to 45 % with the 100-
Figure 1 (See legend on next page.)
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Figure 1 Effect of FABP4 on eNOS activation and NO production in HUVECs. A, effect of FABP4 on eNOS phosphorylation at Ser1177.
HUVECs were incubated with FABP4 at the indicated concentrations for 30 minutes. B, eNOS Ser1177 phosphorylation in response to various
doses of insulin (100, 300, 600 nM). HUVECs were incubated with insulin at the indicated concentrations for 30 minutes. C, Time course of eNOS
Ser1177 phosphorylation in response to insulin. HUVECs were incubated with 600 nM insulin for 10, 30 and 60 min. D, effect on insulin-stimulated
eNOS phosphorylation at Ser1177. HUVECs were incubated with FABP4 at the indicated concentrations for 30 minutes and then with insulin (600
nM) for 30 minutes. E, effect of FABP4 on NO production. HUVECs were incubated with FABP4 at indicated concentrations for 30 minutes and
then stimulated with insulin (600 nM for 30 min). Representative blots are shown. The data are given as the mean± standard deviation from
three independent experiments. *P< 0.05 vs. insulin(−) / FABP4(−); #P< 0.05 vs. insulin(+) / FABP4(−).
Figure 2 Effect of FABP4 on eNOS mRNA expression. HUVECs
were incubated with FABP4 at the indicated concentrations for
30 minutes and then with insulin (600 nM) for 24 hours. TNFα
(10 ng/ml) was used as a negative control. The data are expressed
using the 2-ΔΔCt method. *P< 0.05 vs. insulin(−) / FABP4(−); #P< 0.05
vs. insulin(+) / FABP4(−).
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changes in the total protein levels. Therefore, we exam-
ined the effect of FABP4 on the ability of eNOS to pro-
duce NO under insulin-stimulated conditions. The
change in eNOS phosphorylation at Ser1177 was accom-
panied by a significant decrease in the NO production
of up to 68 % by treatment with 100 ng/ml of FABP4 (P
< 0.05) (Figure 1E). Thus, FABP4 can inhibit both the
basal and the insulin-stimulated eNOS phosphorylation
at Ser1177 and can cause the inactivation of eNOS and
decrease NO production in endothelial cells.
FABP4 inhibits insulin-stimulated eNOS mRNA expression
in HUVECs
Upon insulin stimulation, the eNOS mRNA was
increased in the vascular endothelial cells. As was
expected, insulin augmented the mRNA expression of
eNOS after 24 hours of treatment (P <0.05). The upre-
gulation of insulin-stimulated eNOS expression was
inhibited by 63 % and 59 % due to the treatment with
50 ng/ml and 100 ng/ml of FABP4, respectively
(P< 0.05) (Figure 2). Additionally, we found a 93 % de-
crease in the eNOS expression after an exposure to
TNFα (10 ng/ml) as positive control (P< 0.05).
FABP4 effect on eNOS is produced through the
insulin-signalling pathway in HUVECs
Since insulin activates eNOS through IRS1 and Akt
pathway, we then investigated whether FABP4 have any
effects on insulin-stimulated IRS1 and Akt activation,
which was monitored by phosphorylation at Tyr989 and
Ser473 sites, respectively. The addition of insulin to
HUVECs increases about 25 % the phosphorylation of
IRS1 at Tyr989 (Figure 3A), but a 30-min pretreatment
with FABP4 (25–100 ng/ml) inhibits this insulin-
dependent increase by up to 44 % with the 100-ng/ml
concentration (P< 0.05). No variations were observed in
the total IRS1 protein level across the different FABP4
concentration treatments. There was also a similar effect
of the FABP4 treatment on the phosphorylation of Akt
at Ser473. The insulin stimulation significantly increased
the phosphorylation of Akt at Ser473 (Figure 3B). The
FABP4 pretreatment impaired this insulin-mediated
phosphorylation of Akt at Ser473 by up to 75 % with the100 ng/ml concentration (P< 0.05) in the absence of
any change in protein levels. Collectively, FABP4 inhib-
ited insulin-stimulated phosphorylation of IRS1 and Akt,
indicating possible impairment of upstream insulin-
signalling pathway.
In Figure 4, we analysed whether FABP4 was able to
be internalized within the endothelial cells. We observed
that incubation of HUVECs with 25–100 ng/ml FABP4
for 30 min increased the amount of exogenous FABP4 in
the treated cells compared with the untreated cells
(P< 0.05).
Discussion
The present study demonstrates that exogenous FABP4
induces endothelial cell dysfunction in vitro, as assessed
by the impact on one of their main properties, the vaso-
dilatory mechanisms. We have also shown that this ef-
fect is mediated by the interaction of FABP4 with the
insulin-signalling pathway in vascular cells. FABP4 alters
eNOS activation, as was demonstrated by the reduction
Figure 3 Effect of FABP4 on IRS1 and Akt activation in HUVECs. A, effect on insulin-stimulated IRS1 phosphorylation at Tyr989. B, effect on
insulin-stimulated Akt phosphorylation at Ser473. HUVECs were incubated with FABP4 at the indicated concentrations for 30 minutes and then
with insulin (600 nM) for 30 minutes. Representative blots are shown. The data are given as the mean± standard deviation from three
independent experiments. *P< 0.05 vs. insulin(−) / FABP4(−); #P< 0.05 vs. insulin(+) / FABP4(−).
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In addition, the reduction of IRS1 phosphorylation at
Tyr989 and Akt phosphorylation at Ser473 suggests that
the effect observed for eNOS activation is due to the
interference of FABP4 in the insulin-signalling pathway
in endothelial cells. Our results support a direct effect of
extracellular FABP4 on vascular cells and, therefore, a
putative effect of circulating FABP4 on peripheral tis-
sues. This observation is important because FABP4 is
recognised as a biomarker of cardiometabolic risk but it
could be considered as mediator of peripheral tissue
damage. Several studies have linked FABP4 levels to
obesity, T2D and MS [4,8,11]. Additionally, FABP4 has
been associated with the burden of coronary atheroma-
tosis, but a causal role has not yet been established. The
only report that showed a direct effect of FABP4 on cells
demonstrated that FABP4 reduces the contractile cap-
acity of cardiomyocytes [15]. We have previously
reported that plasma FABP4 levels are associated with
endothelial dysfunction in diabetic patients [16]. Our
present data supports a causal role of FABP4 in the dys-
function of the vascular wall. These findings are in ac-
cordance with a previous study suggesting that an
elevated expression of intracellular FABP4 in vascularendothelial cells contributes to endothelial dysfunction
both in vivo and in vitro [22]. In contrast, a recent study
showed that FABP4/5 inhibitors ameliorate dyslipidae-
mia but not insulin resistance in diet-induced obese
mice [23]. Our results show that exogenous FABP4 alters
the insulin-signalling pathway at its early activation steps.
Additionally, it has already been shown that FABP4 inter-
feres with the insulin receptor [24]. Moreover, FABP4
could be phosphorylated on Tyr19 in response to insulin
stimulation [25]. Our results support these previous obser-
vations and extend them to the exogenous FABP4, which
has a greater clinical implication. Along with a decrease in
eNOS expression, in our hands, FABP4 increased the ex-
pression of vascular cell adhesion protein 1 (VCAM1), E-
selectin and leukocyte adhesion to endothelial cells (data
not shown), suggesting a more global effect of FABP4 on
endothelial function. In our experiments, HUVECs were
stimulated with 600nM insulin because that was the dose
with which we observed an increase in the phospho-eNOS
produced and because other authors also obtained max-
imal nitric oxide production with similar dose [26].
The mechanisms that FABP4 utilises to interfere with
the cell are currently being investigated. Although previ-
ous studies showed that Heart-FABP (62 % homology
Figure 4 FABP4 analysis in total cell lysates. HUVECs were
treated with the indicated concentrations of FABP4 for 30 minutes
followed by 600 nM insulin for 30 minutes. Representative blots are
shown. The data represent the mean± standard deviation from
three independent experiments. *P< 0.05 vs. the untreated control.
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brane receptor described in cardiac cells [27], this obser-
vation has neither been confirmed nor extended to other
FABP family members. It has been shown that heart
FABP levels in serum could represent a useful biomarker
for myocardial function in pre-diabetic patients [28]. It
is not known whether FABP4 interacts directly with the
insulin receptor or if it interacts with other components
of the cell membrane and then secondarily modifies the
insulin cascade. It is also unknown whether circulating
FABP4 can be internalised into the cell to act by intra-
cellular mechanisms. We have observed that the amount
of intracellular FABP4 increases after FABP4 incubations
with respect to non-treated cells, which suggests that
FABP4 could be internalised by endothelial cells. FABP4
is an intracellular long-chain fatty acid transporter
[1,29]. Although this function has not yet been demon-
strated for circulating FABP4, we cannot exclude that
the effects associated with extracellular FABP4 could be
mediated by fatty acids, which are molecules known to
play a role in the dysfunction of the insulin-signalling
pathway. This finding could be important evidence that
FABP4 plays a pivotal role in impairing the insulin sig-
nalling pathway.
Our findings suggest that high levels of FABP4 in the
plasma are not just a clinical manifestation of insulin re-
sistance but also a causative factor of the developmentof insulin resistance at the vascular level leading to NO
metabolism alteration.
Conclusions
In summary, we have demonstrated that FABP4 can
modulate the insulin-signalling pathway in vascular cells
and, consequently, decrease eNOS activation and NO
production, which impairs arterial vasodilatation. Our
results supports that FABP4 plays a direct causal role in
endothelial dysfunction and could be a good therapeutic
target for patients with T2D.
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